These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 15100724)

  • 1. Neurocognitive enhancement: what can we do and what should we do?
    Farah MJ; Illes J; Cook-Deegan R; Gardner H; Kandel E; King P; Parens E; Sahakian B; Wolpe PR
    Nat Rev Neurosci; 2004 May; 5(5):421-5. PubMed ID: 15100724
    [No Abstract]   [Full Text] [Related]  

  • 2. Cognitive enhancement: promises and perils.
    Hyman SE
    Neuron; 2011 Feb; 69(4):595-8. PubMed ID: 21338872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroethical issues in cognitive enhancement.
    Sahakian BJ; Morein-Zamir S
    J Psychopharmacol; 2011 Feb; 25(2):197-204. PubMed ID: 20212064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New drug development for cognitive enhancement in mental health: challenges and opportunities.
    Insel T; Krystal J; Ehlers M
    Neuropharmacology; 2013 Jan; 64():2-7. PubMed ID: 23145450
    [No Abstract]   [Full Text] [Related]  

  • 5. Preface to cognitive enhancement.
    Kantak KM; Wettstein JG
    Handb Exp Pharmacol; 2015; 228():v. PubMed ID: 26317138
    [No Abstract]   [Full Text] [Related]  

  • 6. The changing face of insulin receptors.
    Darlington CL
    Curr Opin Investig Drugs; 2007 Nov; 8(11):885-6. PubMed ID: 17979021
    [No Abstract]   [Full Text] [Related]  

  • 7. Cognitive Enhancement: Treating or Cheating?
    Whetstine LM
    Semin Pediatr Neurol; 2015 Sep; 22(3):172-6. PubMed ID: 26358427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive enhancers: molecules, mechanisms and minds.
    Frenguelli BG
    Neuropharmacology; 2013 Jan; 64():1. PubMed ID: 22985720
    [No Abstract]   [Full Text] [Related]  

  • 9. The Mind Bending Quest for Cognitive Enhancers.
    Arce E; Ehlers MD
    Clin Pharmacol Ther; 2017 Feb; 101(2):179-181. PubMed ID: 27706806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs for cognitive loss and dementia.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):155-161. PubMed ID: 28922342
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison table: drugs for Alzheimer's disease.
    Med Lett Drugs Ther; 2017 Sep; 59(1530):e160-e161. PubMed ID: 28922344
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs for cognitive loss and dementia.
    Treat Guidel Med Lett; 2010 Mar; 8(91):19-24. PubMed ID: 20179667
    [No Abstract]   [Full Text] [Related]  

  • 13. Experts urge smart thinking on cognitive enhancers.
    Morris K
    Lancet Neurol; 2008 Jun; 7(6):476-7. PubMed ID: 18485312
    [No Abstract]   [Full Text] [Related]  

  • 14. Part III. Developmental disorders, alternative approaches, and emerging technologies.
    Handb Exp Pharmacol; 2015; 228():305-7. PubMed ID: 26317141
    [No Abstract]   [Full Text] [Related]  

  • 15. Memory enhancement: the progress and our fears.
    Gerlai R
    Genes Brain Behav; 2003 Aug; 2(4):187-8; discussion 189-90. PubMed ID: 12953784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs influencing cognitive function.
    Kuruvilla A; Devi V
    Indian J Physiol Pharmacol; 1994 Oct; 38(4):241-51. PubMed ID: 7883287
    [No Abstract]   [Full Text] [Related]  

  • 17. [Neuroethics of pharmaceutical cognitive enhancement: the first ten years: current problems and practical guiding principles].
    Metzinger TK
    Fortschr Neurol Psychiatr; 2012 Jan; 80(1):36-43. PubMed ID: 22234814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Part 1. Basic approaches and perspectives.
    Handb Exp Pharmacol; 2015; 228():1-3. PubMed ID: 26317139
    [No Abstract]   [Full Text] [Related]  

  • 19. Part II. Cognitive domains for pharmacological intervention: implications for neuropsychiatric and neurological illnesses.
    Handb Exp Pharmacol; 2015; 228():157-9. PubMed ID: 26317140
    [No Abstract]   [Full Text] [Related]  

  • 20. Correspondence on ''the unrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production''.
    Duane DD
    J Child Neurol; 2009 Dec; 24(12):1578; author reply 1579. PubMed ID: 19955348
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.